A randomized, double-blind, multi-center, phase II fixed dose study of multiple doses of ipilimumab (MDX-010) monotherapy in patients with previously treated unresectable stage III or IV melanoma

Trial Profile

A randomized, double-blind, multi-center, phase II fixed dose study of multiple doses of ipilimumab (MDX-010) monotherapy in patients with previously treated unresectable stage III or IV melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 13 Nov 2007 Status changed from in progress to completed.
    • 15 Jan 2007 Status change
    • 31 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top